Last updated: 31 December 2018 at 3:23am EST

Associates, L.L.C.Morenstei... Net Worth




The estimated Net Worth of Associates, L.L.C.Morenstei... is at least 2.17 百万$ dollars as of 26 December 2018. Associates Morenstei owns over 25,000 units of Molecular Templates Inc stock worth over 2,170,410$ and over the last 6 years Associates sold MTEM stock worth over 0$.

Associates Morenstei MTEM stock SEC Form 4 insiders trading

Associates has made over 1 trades of the Molecular Templates Inc stock since 2018, according to the Form 4 filled with the SEC. Most recently Associates bought 25,000 units of MTEM stock worth 86,250$ on 26 December 2018.

The largest trade Associates's ever made was buying 25,000 units of Molecular Templates Inc stock on 26 December 2018 worth over 86,250$. On average, Associates trades about 25,000 units every 0 days since 2018. As of 26 December 2018 Associates still owns at least 1,584,241 units of Molecular Templates Inc stock.

You can see the complete history of Associates Morenstei stock trades at the bottom of the page.



What's Associates Morenstei's mailing address?

Associates's mailing address filed with the SEC is 2, 731 Alexander Rd, Princeton, NJ 08540, USA.

Insiders trading at Molecular Templates Inc

Over the last 7 years, insiders at Molecular Templates Inc have traded over 22,993,582$ worth of Molecular Templates Inc stock and bought 14,744,530 units worth 82,519,716$ . The most active insiders traders include Target N Vbb Biotech Ag Bio...David HirschCapital Partners Iii, Llc L.... On average, Molecular Templates Inc executives and independent directors trade stock every 47 days with the average trade being worth of 532,718$. The most recent stock trade was executed by Target N Vbb Biotech Ag Bio... on 2 April 2024, trading 250,000 units of MTEM stock currently worth 587,500$.



What does Molecular Templates Inc do?

molecular templates (mtem) is a clinical-stage biopharmaceutical company targeting a variety of cancers through development of its innovative proprietary engineered toxin body (etb) platform. mtem’s first immunotoxin, mt-3724, is in clinical development for non-hodgkin’s lymphoma. pipeline products for additional oncology targets are being advanced toward clinical development. for more information, please visit mtem’s website at www.mtem.com.



Complete history of Associates Morenstei stock trades at Molecular Templates Inc

インサイダー
取引
取引
合計金額
Associates, L.L.C.Morenstei...
購入する 86,250$
26 Dec 2018


Molecular Templates Inc executives and stock owners

Molecular Templates Inc executives and other stock owners filed with the SEC include: